A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
The purpose of this study is to determine the efficacy and safety of crizotinib combined with CHOP chemotherapy for patients with ALK(+) Systemic Anaplastic Large Cell Lymphoma.
Systemic Anaplastic Large-Cell Lymphoma
DRUG: crizotinib
complete remission rate, 2 years
disease-free survival, 2 years|overall survival, 2 years|objective response rate, 2 years|incidence of >/Grade 3 non-hematology toxicity adverse events, 2 years|QOL assessment, using a battery of cognitive and quality-of-life (QoL) measures, 2 years
ALK(+) Systemic Anaplastic Large Cell Lymphoma patients are treated with crizotinib when they receive CHOP chemotherapy. crizotinib 250mg twice a day is administrated from day 1 of chemotherapy to 18 weeks. standard CHOP chemotherapy (cyclophosphamide, 750mg per square meter of body-surface area,d1, vincristine, 1.4mg per square meter of body-surface area, maximal dose is 2mg d1, doxorubicin, 50mg per square meter of body-surface area d1, plus prednison, 100 mg d1-5) every 3 weeks for up to six cycles.